Founder profile
Vladimir Mitev
Founder and CEO, Helena Bioinformatics
Vladimir Mitev is the founder and CEO of Helena Bioinformatics, a bioinformatics company based in Sofia, Bulgaria. He leads the development of Folklore and the company's work across genomic interpretation, computational infrastructure and scientific collaboration.
Current work
Building infrastructure for genomic interpretation
At Helena Bioinformatics, Vladimir leads product architecture, software engineering, infrastructure, company strategy and commercial deployment.
His primary product work is Folklore, Helena Bioinformatics's proprietary platform for genomic variant interpretation and case-based genomic analysis. Folklore brings classification, phenotype, inheritance and literature evidence into one case record for specialist review.
His work also includes reproducible genomics research, public computational studies and collaboration with laboratories, universities and scientific organisations.
Areas of work
Bioinformatics
Genomic variant interpretation
Clinical genomics software
Cancer genomics
Reproducible computational research
Scientific and laboratory collaboration
Selected public research
Robustness and cross-cohort concordance of developmental regulons in endometrial carcinoma
A public computational study repository containing the analysis record, reproducibility materials and project documentation.
The study separates association, target-set robustness and transportability across cohorts. It evaluates developmental regulons in TCGA-UCEC and compares selected signals with CPTAC-UCEC. The public record explains which signals retained their direction and which remained unresolved, with limits on causal and clinical interpretation.
Vladimir is listed as corresponding author alongside Draga Toncheva and Vasil Sgurev. The repository contains the computational analysis and provenance material; the research section of this website links the preprint and archived release. Readers can use those records to inspect the methods and evidence behind the summary, rather than treating the founder profile as a substitute for the study.
The analysis asks whether developmental regulon signals in endometrial carcinoma survive changes in target composition and retain their direction in an independent cohort. It keeps pointwise association, target-set robustness and cross-cohort transportability as separate claims.
Twenty prespecified developmental transcription-factor regulons and a fetal Mullerian epithelial module were evaluated in 507 TCGA-UCEC tumours. Six signals were then assessed in 230 CPTAC-UCEC tumours. The global fetal module was non-confirmatory.
GATA2 and SOX9 retained the same direction across cohorts but failed the universal single-target-deletion gate. HOXA9 and WT1 lacked external confirmation. PAX8 and LHX1 were internally robust but remained externally unresolved.
The results support directional concordance for selected regulons. They do not establish causal transcription-factor activity, biomarker validity, therapeutic dependence, treatment response or clinical utility. The preprint has not been peer reviewed.
View the research repository